Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OLINVYK vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Oliceridine is a G protein-biased μ-opioid receptor agonist. It preferentially activates the G protein pathway (associated with analgesia) over β-arrestin recruitment (associated with opioid-related adverse effects like respiratory depression and gastrointestinal dysfunction).
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Management of acute pain severe enough to require an intravenous opioid analgesic and for which alternative treatments are inadequate
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Initial adult dose: 1.5 mg intravenously (IV) every 3 to 6 hours as needed. May be titrated in increments of 0.75 mg to 1.5 mg every 3 to 6 hours. Maximum single dose: 4.5 mg. Maximum daily dose: 27 mg.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life is approximately 26–29 hours, supporting once-daily dosing in chronic pain
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Primarily metabolized by CYP3A4 and CYP2D6 to inactive metabolites; also undergoes glucuronidation.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily renal (approximately 90% as unchanged drug and metabolites); biliary/fecal excretion accounts for <5%
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Approximately 93–95% bound to albumin and alpha-1-acid glycoprotein
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 3.5–4.5 L/kg, indicating extensive tissue distribution
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: approximately 70% for extended-release formulation; intravenous: 100%
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
For GFR 15 to 29 m L/min: reduce dose by 50% and monitor for respiratory depression. For GFR <15 m L/min: not recommended. For dialysis: not recommended.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh Class A: no adjustment needed. Child-Pugh Class B: reduce dose by 50%; consider reducing dose frequency. Child-Pugh Class C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Not approved for use in pediatric patients under 18 years of age; safety and efficacy not established.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initial dose: 1.5 mg IV every 3 to 6 hours; consider dose reduction to 0.75 mg in patients aged 65 years or older due to increased sensitivity and risk of respiratory depression.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; accidental ingestion; risks from concomitant use with benzodiazepines or CNS depressants; neonatal opioid withdrawal syndrome; and risks associated with use in patients with compromised respiratory function, especially in elderly, cachectic, or debilitated patients.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Life-threatening respiratory depression; addiction, abuse, and misuse; neonatal opioid withdrawal syndrome; risks from concomitant use with benzodiazepines or CNS depressants; severe hypotension; adrenal insufficiency; seizure; and withdrawal.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected gastrointestinal obstruction, including paralytic ileus; hypersensitivity to oliceridine.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
No specific food interactions. Grapefruit juice has no known interaction. Avoid alcohol consumption due to additive CNS depression.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome. First trimester: Limited data, but opioids as a class are not major teratogens. Second/third trimester: Chronic use may lead to fetal dependence and withdrawal postnatally. Use only if benefit outweighs risk, especially near term.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Oliceridine is excreted in human milk; M/P ratio not available. Breastfeeding not recommended due to potential for infant sedation and respiratory depression. If used, monitor infant for drowsiness, feeding difficulties, and respiratory rate.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Pregnancy may alter pharmacokinetics of oliceridine (increased clearance, volume of distribution). No specific dose adjustment guidelines exist; titrate to effective dose and monitor closely for both efficacy and adverse effects.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
OLINVYK (oliceridine) is a mu-opioid receptor agonist with reduced beta-arrestin recruitment, potentially offering a therapeutic window with less respiratory depression at equianalgesic doses. Requires ECG monitoring due to QTc prolongation; avoid in patients with history of long QT syndrome or concurrent QT-prolonging drugs. Do not use more than 27 mg in a 24-hour period due to hepatic metabolite accumulation. Administer only in a hospital setting for short-term intravenous use (≤48 hours).
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
OLINVYK is a strong pain medicine that can cause serious side effects like slowed breathing, low blood pressure, and heart rhythm changes.,Tell your healthcare provider right away if you feel dizzy, lightheaded, or faint, or if you have a fast or irregular heartbeat.,Do not stop taking this medicine suddenly, as withdrawal symptoms may occur.,Do not drive or operate heavy machinery while receiving this medication.,This drug may cause constipation; increase fluid intake and request stool softeners if needed.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OLINVYK vs ABSTRAL, answered by our medical review team.
OLINVYK is a Opioid Analgesic that works by Oliceridine is a G protein-biased μ-opioid receptor agonist. It preferentially activates the G protein pathway (associated with analgesia) over β-arrestin recruitment (associated with opioid-related adverse effects like respiratory depression and gastrointestinal dysfunction).. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OLINVYK and ABSTRAL depend on the specific clinical indication. These are both Opioid Analgesic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OLINVYK is: Initial adult dose: 1.5 mg intravenously (IV) every 3 to 6 hours as needed. May be titrated in increments of 0.75 mg to 1.5 mg every 3 to 6 hours. Maximum single dose: 4.5 mg. Maximum daily dose: 27 mg.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OLINVYK and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OLINVYK is classified as Category C. Prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome. First trimester: Limited data, but opioids as a class are not major teratogens. Second/. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.